MEIP News and Press, MEI Pharma Inc. From 09/22/22

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decided to retire and thus does not intend to stand for reelection at the Company’s fiscal year 2023 annual meeti...

The following slide deck was published by MEI Pharma, Inc. in conjunction with this event. For further details see: MEI Pharma (MEIP) Investor Presentation - Slideshow

MEI Pharma ( NASDAQ: MEIP ) stock rose ~3% on Sept. 9 after FY22 revenue increased ~17% Y/Y. For the fiscal year ended June 30 2022, revenue amounted to ~$40.9M, compared to ~$34.8M in 2021. Net loss widened to -$54.5M, compared to -$41.3M in the prior y...

MEI Pharma, Inc. (MEIP) Q4 2022 Results Conference Call September 08, 2022 05:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer Davi...

MEI Pharma press release ( NASDAQ: MEIP ): FY GAAP EPS of -$0.50 misses by $0.03 . Revenue of $40.7M (+17.0% Y/Y) misses by $1.09M . The adjusted net loss was $75.2 million, compared to an adjusted net loss of $59.4 million for 2021. As of June 30, 2022, ME...

-MEI Begins Fiscal Year 2023 with $153 Million in Cash- - Conference Call Today at 5:00 p.m. Eastern Time - MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright 24 th Annual Global Investment Conference 2022. The company will present a company overview and business updat...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022. The Company wi...

Summary Kodiak Sciences busted earlier this year as its first of six pivotal Phase 3 trials on its lead compound, tarcocimab, failed its very poorly designed clinical trial. Subsequent to us taking a stake, Kodiak announced positive data on its most recent registration trial BEACO...

Summary Our US-denominated Global Micro Fund was down 16.6% in the quarter, and is down 21.0% for the year. We are taking advantage of the current turmoil in the markets, adding a new busted Biotech (KOD), and adding substantially to MEI Pharma and Liberty Tripadvisor - among othe...